Recent news on Macugen

Thousands losing sight in NHS postcode lottery  -  May 22, 2007
Telegraph.co.uk,Even those doctors who can get the drugs, sold as Lucentis and Macugen, are only able to obtain them in certain circumstances.

Study Fails to Demonstrate Differences between Intravitreal ...  -  May 14, 2007
DG NewsMacugen was administered every 6 weeks and PDT could be repeated if retinal leakage was seen on fluorescein angiography at three months.

Study finds little further benefit from Avastin after prior ...  -  May 10, 2007
OSN SuperSite (subscription),Using Avastin to treat choroidal neovascularization secondary to age-related macular degeneration in patients previously treated with Macugen results in

PCT will pay for eye drug  -  May 19, 2007
Norfolk Eastern Daily Press,The PCT has previously provided photodynamic therapy (PDT) for wet-AMD but the focus is now on new, more effective, drugs - Macugen, Lucentis and Avastin

Ranibizumab, Bevacizumab and Pegaptanib All Cause Post-Injection ...  -  May 7, 2007
DG NewsThe patients received a total of 75 injections of Macugen (0.09 mL every six weeks), 69 injections of Avastin (0.05 mL as needed), and 25 injections of

Retinal Pigment Epithelial Tears Associated With Bevacizumab ...  -  May 14, 2007
DG NewsRetinal pigment epithelial tears are not unique to Avastin and have been seen in patients treated with pegaptanib (Macugen), ranibizumab (Lucentis),

Eye treatment withheld over 'secret bans'  -  Apr 28, 2007
Telegraph.co.uk,Fewer than 2 per cent of the 16000 people who could have benefited from Macugen, a treatment for age-related macular degeneration, the biggest cause of

Will there soon be a cure for everything?  -  May 1, 2007
Belfast Telegraph,Macugen, given by injection directly into the eye, halts the loss of vision in up to half of patients, and Lucentis has been shown to reverse it,

New medication and other hope for age-related impaired vision  -  May 1, 2007
Dallas Morning News (subscription),Two FDA-approved drugs, Macugen and Lucentis, can be injected into the eye. "Certainly, it sounds a bit shocking, but it's really pretty minimally invasive,

Shedding Light On Macular Degeneration  -  May 23, 2007
eMaxHealth.com,Macugen, approved by the FDA in 2004, stops formation of new abnormal blood vessels and decreases leakage from existing ones. It's injected directly into

VCs Look for Cure to an Eye Disease  -  May 16, 2007
Forbes,Macugen, which inhibits vessel formation, earned US approval in 2004 and propelled Eyetech to an initial public offering that year.

VEGF inhibitors face regulatory, availability problems in France  -  May 17, 2007
OSN SuperSite (subscription),Macugen (pegaptanib sodium, OSI/Pfizer) was authorized for sale in France in January 2006, but Lucentis (ranibizumab, Genentech) can only be licensed for

Zacks Bull and Bear of the Day Highlights: Cirrus Logic, Whole ...  -  May 14, 2007
Business Wire (press release),We expect the company to divest Macugen around mid-year. In the meantime, OSI must prove to the Street there is more to the name than just Tarceva and

Three new medical drugs achieve improvement in sight loss caused ...  -  Apr 24, 2007
Basque Research,The three pharmaceutical drugs are members of the anti-angiogenic family, marketed under the names of Macugen, Lucentis and Avastin.

eXegenics Inc.: New Company; New Technology  -  Apr 18, 2007
Seeking Alpha,Another marketed therapeutic is Macugen, which is a pegylated aptamer (tight binding oligonucleotide) and was developed by Eyetech and licensed to Pfizer;

The war hero who faces selling his home for the drugs to save his ...  -  Apr 12, 2007
This is London,In England, the drugs watchdog the National Institute for Health and Clinical Excellence has not yet given the go-ahead for either Lucentis or Macugen,

QLT says CHMP to recommend deleting 'occult' indication of ...  -  Apr 25, 2007
Forbes,...from Genentech Inc (nyse: DNA - news - people )'s rival drug Lucentis and OSI Pharmaceuticals Inc (nasdaq: OSIP - news - people )'s rival drug Macugen.

Enzon's PEG-SN38 Shows Anti-Tumor Activity in Resistant ...  -  Apr 18, 2007
PipelineReview.com (press release),...two of which Enzon markets, Adagen(R) and Oncaspar(R), and three for which Enzon receives royalties, PEG-INTRON(R), Pegasys(R), and Macugen(R).

News For Your Web Site  -  Apr 18, 2007
dBusinessNews Newark (press release),...two of which Enzon markets, Adagen® and Oncaspar®, and three for which Enzon receives royalties, PEG-INTRON®, Pegasys®, and Macugen®.

Enzon’s PEG-SN38 Shows Anti-Tumor Activity in Resistant ...  -  Apr 17, 2007
Business Wire (press release),...two of which Enzon markets, Adagen ® and Oncaspar ® , and three for which Enzon receives royalties, PEG-INTRON ® , Pegasys ® , and Macugen ® .

Stocks: OSI pays off after a long wait  -  Apr 16, 2007
Crain's New York Business,The company paid $650 million in 2005 to purchase Eyetech Pharmaceuticals Inc. — largely to gain control of Macugen, a drug for the treatment of blindness

Old folk go blind as NHS cuts costs  -  Apr 14, 2007
Norfolk Eastern Daily Press,...despite consultants at the Norfolk and Norwich University Hospital recommending its use for the condition - ahead of alternatives Lucentis and Macugen.

Only taking on health service will save our sight  -  Apr 12, 2007
Norfolk Eastern Daily Press,Cash-strapped primary care trusts are reluctant to fund any of the three drugs which can be used, Avastin, Lucentis and Macugen.

Enzon Enrolls First Patient in Phase 1 Study of Its HIF-1 Alpha ...  -  Mar 29, 2007
PipelineReview.com (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and Macugen(R), marketed by OSI

NHS won't pay for sight-saving drug  -  Mar 20, 2007
ic Wales,The National Institute for Health and Clinical Excellence (Nice) is due to issue guidance on the funding of the drugs Macugen and Lucientus in September

OSI Eyeing Growth in '07  -  Feb 27, 2007
Motley FoolMacugen is a treatment option for patients suffering from macular degeneration. OSI has partnered with Pfizer (NYSE: PFE) to market it, and the company

Women fight for their sight  -  Mar 9, 2007
Cambridge Evening News,Another drug successful in the treatment of wet AMD, called Macugen, has been given the approval of the Scottish Medicines Consortium for prescription on

Panel looks at immediate future for AMD treatments  -  Mar 2, 2007
OSN SuperSite (subscription),Dr. Puliafito: Does anyone feel that the fluid-free interval is longer for Avastin compared with Lucentis and Macugen? Dr. Rosenfeld: It is so variable

Samir Patel, MD Appointed To The Board of Mimetogen Pharmaceuticals  -  Mar 1, 2007
PharmaLive.com (press release),He was part of the senior management team responsible for the development of the clinical protocols leading to the FDA approval of Macugen for macular

FURY OVER OAP EYE DRUG SNUB  -  Mar 6, 2007
Glasgow Daily Record,The drugs they need - Lucentis or Macugen - are licensed for use on the NHS but haven't been approved by the Government's drug rationing body, NICE.

Cramer is right on with Gilead Sciences  -  Mar 1, 2007
Blogging StocksThe drug Macugen is another blockbuster treating this wicked disease. The company has many other potential drugs in various stages of clinical trials,

Piper Jaffray Starts OSI Coverage  -  Mar 22, 2007
Forbes,The company bought Eyetech in 2005 for its macular degeneration drug Macugen, which has seen sales slide against Lucentis, made by Genentech Inc.

Jerini Announces Establishment of Wholly-Owned US Subsidiary Aimed ...  -  Mar 20, 2007
PharmaLive.com (press release),2004 FDA approval, and market launch of Macugen®, the first anti- vascular endothelial growth factor (VEGF) drug for ophthalmology.

Tracon Licenses D93 Antibody From Micromet  -  Mar 18, 2007
BioWorld Online,Schering AG and Biogen Idec Inc.), Sutent (sunitinib, Pfizer Inc.), Macugen (pegaptanib, OSI Pharmaceuticals Inc. and Pfizer Inc.) and other drugs.

Isis Pharmaceuticals Reports Financial Results and Highlights for ...  -  Mar 8, 2007
Earthtimes.orgIsis received $8 million from Drug Royalty USA, Inc. related to Macugen. * Isis received a milestone payment from iCo Therapeutics based on its filing of an

Isis Pharmaceuticals Reports Financial Results and Highlights for ...  -  Mar 8, 2007
Genetic Engineering News (press release),...respectively, of revenue from Drug Royalty USA, Inc. as partial payment for the acquisition of a part of Isis' royalty rights in Macugen(R).

Enzon to Present at Cowen 27th Annual Health Care Conference  -  Mar 6, 2007
Business Wire (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON ® , marketed by Schering-Plough Corporation, and Macugen ® , marketed by OSI

Pharma Sector: Few Newsmakers Of The Week - Lilly, Novartis ...  -  Mar 5, 2007
Trading Markets,Currently approved therapies for macular degeneration like Genentech's Lucentis and Macugen manufactured by Eyetech Pharmaceuticals & Pfizer,

Zacks Bull and Bear of the Day Highlights: EnCana, OSI ...  -  Mar 5, 2007
Business Wire (press release),We expect the company to divest Macugen around mid-year. In the meantime, OSI must prove to the Street there is more to the name than just Tarceva and

PCTs urged to approve use of wet AMD drug  -  Mar 1, 2007
Optician Online,However, the National Institute for Health and Clinical Excellence is expected to spend another nine months reviewing Anti-VEGF treatments such as Macugen

Cost of line of vision in AMD supports need for solutions, surgeon ...  -  Feb 28, 2007
OSN SuperSite (subscription),...$448 for photodynamic therapy, $1248 for Macugen (pegaptanib sodium, OSI/Pfizer) and $687 for Lucentis (ranibizumab, Genentech).

Eye drug private costs 'immoral'  -  Feb 25, 2007
BBC News,The drugs - macugen and lucentis - are being used privately under licence. But they are currently being assessed for NHS use by the National Institute for

OSI 4Q Loss Widens on Macugen Charges  -  Feb 21, 2007
Forbes,Excluding Macugen impairment charges of $212 million but including stock-based compensation costs, the company said it lost 1 cent per share in the latest

OSI Pharmaceuticals Announces Year End 2006 Financial Results  -  Feb 23, 2007
Oxfordshire Bioscience Network (press release),The increase was primarily due to the growth in revenues arising from worldwide Tarceva(R) (erlotinib) sales, and the addition of Macugen(R) (pegaptanib

OSI loss widens, eye drug blamed  -  Feb 22, 2007
Newsday,Impairment charges related to Macugen were $212 million; the company plans to leave the eye care business. When OSI excluded the Macugen-related charges,

TABLE-OSI Pharmaceuticals Q4 net loss widens  -  Feb 21, 2007
Reuters...--The biotechnology company said the latest quarter included impairment charges of $186 million and $26 million related to Macugen intangibles and Macugen

Points of View  -  Feb 13, 2007
The Herald,We have previously, through The Herald, highlighted instances of people with the condition known as "wet AMD" who are at risk of sight loss because Macugen

Pleas for NHS to fund vital eye treatment  -  Feb 13, 2007
Sommerset County Gazette,He had decided to pay £4000 out of saving he had put aside for his funeral to pay for 10 injections of Macugen rather than wait to see if the NHS changed

Conservatives call for end to Lucentis lottery  -  Feb 16, 2007
Optician Online,John Baron, who speaks for the party on ophthalmology, added his voice to the growing criticism over the availability of Lucentis and Macugen.

Woman loses her chance of sight after drug delay  -  Feb 11, 2007
The Herald,Yet she was told as long ago as October that she was a suitable case for the new drug, Macugen, which was cleared for use in July by the executive watchdog,

NHS cash crisis deprives thousands of treatment for blindness  -  Jan 29, 2007
Independent,But many PCTs refuse to fund Lucentis and a rival, Macugen, licensed last year, in advance of an assessment by the National Institute for Clinical

WW2 pilot denied sight-saving drug on NHS  -  Feb 9, 2007
This is London,Mr Reyre's GP and eye specialist both recommended an immediate £4000 course of Macugen, but Somerset Primary Care Trust refused to pay.

Ex-Labour MP's fight over sight drug  -  Jan 30, 2007
ITV.com,Macugen works by targeting a protein that helps the formation of new blood vessels and reduces fluid leakage, a characteristic of wet AMD.

Former MP fights for drug that could save her eyesight  -  Jan 29, 2007
Telegraph.co.uk,Macugen works by targeting a protein that helps the formation of new blood vessels. Treatment with Macugen requires an injection every six weeks.

Health boards told to use sight-saving treatment  -  Feb 1, 2007
The Herald,The Royal National Institute of the Blind has championed the demand for treatment using the drug Macugen in Scotland. Yesterday the SNP MSP Stewart Maxwell

Ex MP battles NHS over eye drug  -  Jan 29, 2007
BBC News,Two of the treatments only help a small percentage of patients, but two new drugs, Macugen and Lucentis, are suitable for most patients.

‘Lack of staff’ preventing sight-saving treatment  -  Jan 30, 2007
The Herald,The drug, Macugen, has been approved for use since last year, but many health authorities initially claimed they could not afford to supply it.

Ex-MP in legal battle to keep sight  -  Jan 30, 2007
ic Huddersfield.co.uk,But two new drugs - Macugen (pegaptanib), which costs about £10000 a year, and Lucentis, which costs around £12000 - are suitable for most patients.

Una's anger at sight treatment  -  Jan 29, 2007
Nortthamptonshire Chronicle and Echo,Last year, health professionals became concerned about Mrs Ridley's sight and in September recommended her for treatment with the drug Macugen,

Genentech warns on blindness treatment  -  Jan 27, 2007
Los Angeles Times,Lucentis also competes with OSI Pharmaceuticals Inc.'s Macugen. The Melville, NY-based company said it planned to get out of the eye disease business,

Genentech's Lucentis Stroke Risk Rises in Higher Dose (Update2)  -  Jan 26, 2007
BloombergLucentis also competes with OSI Pharmaceuticals Inc.'s Macugen. The Melville, New York-based company said it plans to get out of the eye disease business,

Company Profile for TRACON Pharmaceuticals, Inc.  -  Feb 9, 2007
Business Wire (press release),The management team has led or contributed to the development of six approved biopharmaceuticals: Rituxan®, Zevalin®, Viracept®, Targretin®, Macugen® and

Company Profile for Tracon Pharmaceuticals, Inc.  -  Feb 9, 2007
PharmaLive.com (press release),...led or contributed to the development of six approved biopharmaceuticals: Rituxan(R), Zevalin(R), Viracept(R), Targretin(R), Macugen(R) and Sutent(R).

New study reveals higher risk with Genentech drug  -  Jan 27, 2007
San Francisco Chronicle,The Lucentis data may open marketing opportunities for manufacturers of the competing drugs Visudyne, made by QLT Inc., and OSI Pharmaceuticals' Macugen.

Spring Is Time For Age-Related Macular Degeneration (AMD) Awareness  -  Feb 22, 2007
Medical News Today (press release),Two drugs have already been approved by the FDA, Macugen and Lucentis, and the makers of several others are looking to gain FDA approval.

Genentech's Big Drug For Eyes Faces a Rival  -  Feb 21, 2007
Wall Street Journal (subscription),..."It's a backdoor to what the UK does," says Anthony Adamis, chief scientific officer for a unit of OSI Pharmaceuticals Inc. that makes Macugen,

Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in ...  -  Feb 15, 2007
Drug Newswire (press release),Revatio for pulmonary arterial hypertension, and Macugen for age-related macular degeneration which can lead to blindness in elderly patients.

Enzon Reports 2006 Financial Results and Accomplishments  -  Feb 13, 2007
Genetic Engineering News (press release),MACUGEN, also as anticipated, experienced significant competition from a newly approved agent. The Company's revenues from its Contract Manufacturing

Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in ...  -  Feb 13, 2007
Earthtimes.orgRevatio for pulmonary arterialhypertension, and Macugen for age-related macular degeneration which can leadto blindness in elderly patients.

Cardiologist questions safety of Avastin use  -  Feb 9, 2007
Optician Online,At the same meeting, health economist Sorrel Wolowacz explained a model showing Macugen treatment to fall well within the NICE recommendations for cost

Claims of postcode lottery on hospital treatment  -  Feb 7, 2007
Sommerset County Gazette,He says he has been told that laser treatment will not help his condition, but that injections of a drug called Macugen will.

Funding can depend on where you live  -  Feb 5, 2007
ic Wales,Macugen for age-related macular degeneration. One patient was funded for treatment in Liverpool at a cost of £6500. Efalizumab at a cost of £9000 a year for

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 4, 2007
dBusinessNews Newark (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON®, marketed by Schering-Plough Corporation, and MACUGEN®, marketed by OSI Pharmaceuticals

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 2, 2007
Business Wire (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON ® , marketed by Schering-Plough Corporation, and MACUGEN ® , marketed by OSI

Enzon Announces Consolidation of Its Manufacturing Operations in ...  -  Feb 2, 2007
Genetic Engineering News (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and MACUGEN(R), marketed by OSI

New cancer target could be as important as VEGF  -  Jan 31, 2007
DrugResearcher.com,EyeTech Pharmaceuticals, in conjunction with Pfizer, markets the anti-VEGF drug Macugen (pegaptanib sodium injection) as a treatment for all types of wet

Ex-MP takes PCT to task over eye treatment  -  Jan 30, 2007
Healthcare Equipment and Supplies,There are two new drugs, Macugen and Lucentis, which could treat this condition, at a cost of £10000 and £12000 a year respectively.

Ex-MP in drug fight to save her sight  -  Jan 29, 2007
This is London,Lucentis was licensed earlier this month but, along with another wet AMD drug called Macugen, will not be considered for approval by the National Institute

Thursday's Health Winners & Losers  -  18 Jan 2007
TheStreet.comSales of Visudyne as well as OSI Pharmaceuticals' (OSIP - commentary - Cramer's Take) drug Macugen have taken a hit since the approval of Genentech's (DNA

Eye injections benefit diabetics, study says  -  Jan 9, 2007
Henderson Gleaner,Adamis said injections of the Eyetech drug Macugen tend to reverse new blood-vessel growth in patients with diabetic retinopathy. The injections are given

Shots in the eye curb diabetic loss of sight  -  Jan 9, 2007
Newsday,The data suggest, he said, that injections of the Eyetech drug Macugen tend to reverse new blood-vessel growth in patients with diabetic retinopathy.

Zacks Bull and Bear of the Day Highlights: Intevac, OSI ...  -  Jan 4, 2007
Business Wire (press release),The Eyetech acquisition was a financial disaster, and Macugen continues to struggle since the approval of Lucentis. A year after the merger, management now

OSI, Eli Lilly to develop new diabetes drugs  -  Jan 6, 2007
Crain's New York Business,...million in the year-earlier period, helped by strong sales of its Tarceva lung cancer treatment, and Macugen, which is used to treat macular degeneration.

OSI: No bonus for CEO  -  Dec 20, 2006
Long Island Business News (subscription),In November 2005, OSI spent more than $900 million in cash and stock to buy Eyetech Pharmaceuticals and its flagship macular degeneration drug, Macugen.

Eye on Genentech's Lucentis  -  Jan 10, 2007
TheStreet.comUnlike its competitors -- Visudyne sold by Novartis (NVS - commentary - Cramer's Take) and Macugen from OSI Pharmaceuticals (OSIP - commentary - Cramer's

Enzon Announces CEO Cancer Gold Standard Accreditation  -  Jan 10, 2007
American Digital Networks (press release),In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and MACUGEN(R), marketed by OSI

Macular degeneration: What you should know  -  Jan 6, 2007
Bradenton Herald,Other treatment options include the drug Macugen, laser surgery and photodynamic therapy. • Eating healthy: Studies suggest that eating antioxidant-rich

Analysts See More Biotech M&A in 2007  -  Dec 26, 2006
Houston Chronicle,Genentech Inc. received FDA approval for its age-related macular degeneration drug Lucentis in June, pitting it against OSI Pharmaceuticals' Macugen.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional